Status:
COMPLETED
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Conditions:
Schizophrenia
Bipolar Disorder
Eligibility:
All Genders
18-80 years
Brief Summary
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
Detailed Description
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder. Qualified schizophrenia patients will be enrolled to an 12-week treatment p...
Eligibility Criteria
Inclusion
- Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to DSM-IV criteria
- Age: more than 18 years of age
Exclusion
- Unqualified patients judged by study investigator(s)
Key Trial Info
Start Date :
April 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT00216723
Start Date
April 1 2004
End Date
December 1 2009
Last Update
October 23 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea
2
Samsung Medical Center
Seoul, South Korea